Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts.

Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30563-5. doi: 10.1016/j.jtho.2019.07.006. [Epub ahead of print]

PMID:
31349062
2.

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC.

Richtmann S, Wilkens D, Warth A, Lasitschka F, Winter H, Christopoulos P, Herth FJF, Muley T, Meister M, Schneider MA.

Cancers (Basel). 2019 May 11;11(5). pii: E652. doi: 10.3390/cancers11050652.

3.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
4.

[Immunophenotyping of lung tumors : An update].

Warth A, Fink L.

Pathologe. 2019 Apr 1. doi: 10.1007/s00292-019-0589-0. [Epub ahead of print] Review. German.

PMID:
30937512
5.

Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.

Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F.

Lung Cancer. 2019 Apr;130:194-200. doi: 10.1016/j.lungcan.2019.02.017. Epub 2019 Feb 19.

6.

E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer.

Klupp F, Giese C, Halama N, Franz C, Lasitschka F, Warth A, Schmidt T, Kloor M, Ulrich A, Schneider M.

Cancer Manag Res. 2019 Feb 22;11:1795-1803. doi: 10.2147/CMAR.S178111. eCollection 2019.

7.

Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.

Kriegsmann K, Cremer M, Zgorzelski C, Harms A, Muley T, Winter H, Kazdal D, Warth A, Kriegsmann M.

Pathology. 2019 Apr;51(3):240-245. doi: 10.1016/j.pathol.2018.11.009. Epub 2019 Feb 21.

PMID:
30798982
8.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A.

Appl Immunohistochem Mol Morphol. 2019 Jan 11. doi: 10.1097/PAI.0000000000000700. [Epub ahead of print]

PMID:
30640754
9.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
10.

Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease.

Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M.

Respiration. 2019;97(4):348-354. doi: 10.1159/000493428. Epub 2018 Dec 14.

PMID:
30554201
11.

Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer.

Weber R, Meister M, Muley T, Thomas M, Sültmann H, Warth A, Winter H, Herth FJF, Schneider MA.

Int J Oncol. 2019 Feb;54(2):515-526. doi: 10.3892/ijo.2018.4654. Epub 2018 Dec 5.

12.

Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations.

Kazdal D, Harms A, Endris V, Penzel R, Oliveira C, Kriegsmann M, Longuespée R, Winter H, Schneider MA, Muley T, Pfarr N, Weichert W, Stenzinger A, Warth A.

Lung Cancer. 2018 Dec;126:80-88. doi: 10.1016/j.lungcan.2018.10.024. Epub 2018 Oct 29.

PMID:
30527196
13.

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC.

Schneider MA, Muley T, Weber R, Wessels S, Thomas M, Herth FJF, Kahn NC, Eberhardt R, Winter H, Heussel G, Warth A, Herold-Mende C, Meister M.

Cancers (Basel). 2018 Dec 4;10(12). pii: E486. doi: 10.3390/cancers10120486.

14.

Targeting LINC00673 expression triggers cellular senescence in lung cancer.

Roth A, Boulay K, Groß M, Polycarpou-Schwarz M, Mallette FA, Regnier M, Bida O, Ginsberg D, Warth A, Schnabel PA, Muley T, Meister M, Zabeck H, Hoffmann H, Diederichs S.

RNA Biol. 2018;15(12):1499-1511. doi: 10.1080/15476286.2018.1553481. Epub 2018 Dec 7.

PMID:
30499379
15.

Tumor Budding and Cell Nest Size Are Highly Prognostic in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: Further Evidence for a Unified Histopathologic Grading System for Squamous Cell Carcinomas of the Upper Aerodigestive Tract.

Boxberg M, Kuhn PH, Reiser M, Erb A, Steiger K, Pickhard A, Straßen U, Koob I, Kolk A, Warth A, Jesinghaus M, Weichert W.

Am J Surg Pathol. 2019 Mar;43(3):303-313. doi: 10.1097/PAS.0000000000001178.

PMID:
30475254
16.

Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.

Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H, Longuespée R, Kriegsmann J, Warth A, Kriegsmann M.

Appl Immunohistochem Mol Morphol. 2018 Oct 24. doi: 10.1097/PAI.0000000000000715. [Epub ahead of print]

PMID:
30358615
17.

Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.

Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, Muley T, Meister M, Sültmann H, Fröhlich H, Kuner R, Lasitschka F.

PLoS One. 2018 Oct 23;13(10):e0206132. doi: 10.1371/journal.pone.0206132. eCollection 2018.

18.

Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.

Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H.

Int J Cancer. 2019 Mar 1;144(5):1061-1072. doi: 10.1002/ijc.31939. Epub 2018 Dec 3.

PMID:
30350867
19.

Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.

Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS.

J Thorac Oncol. 2019 Jan;14(1):72-86. doi: 10.1016/j.jtho.2018.09.008. Epub 2018 Sep 22.

PMID:
30253972
20.

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A.

J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.

21.

Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800034. doi: 10.1002/prca.201800034. Epub 2018 Oct 15.

PMID:
30216696
22.

Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer.

Kriegsmann M, Kriegsmann K, Harms A, Longuespée R, Zgorzelski C, Leichsenring J, Muley T, Winter H, Kazdal D, Goeppert B, Warth A.

Diagn Pathol. 2018 Sep 11;13(1):68. doi: 10.1186/s13000-018-0751-7.

23.

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.

Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800035. doi: 10.1002/prca.201800035. Epub 2018 Aug 21.

PMID:
30035857
24.

Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification.

Melnik S, Dvornikov D, Müller-Decker K, Depner S, Stannek P, Meister M, Warth A, Thomas M, Muley T, Risch A, Plass C, Klingmüller U, Niehrs C, Glinka A.

Cell Discov. 2018 Jul 3;4:37. doi: 10.1038/s41421-018-0033-2. eCollection 2018.

25.

Molecular dissection of large cell carcinomas of the lung with null immunophenotype.

Harms A, Endris V, Winter H, Kriegsmann M, Stenzinger A, Schirmacher P, Warth A, Kazdal D.

Pathology. 2018 Aug;50(5):530-535. doi: 10.1016/j.pathol.2018.03.005. Epub 2018 Jun 27.

PMID:
29958730
26.

Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response.

Dvornikov D, Schneider MA, Ohse S, Szczygieł M, Titkova I, Rosenblatt M, Muley T, Warth A, Herth FJ, Dienemann H, Thomas M, Timmer J, Schilling M, Busch H, Boerries M, Meister M, Klingmüller U.

Sci Rep. 2018 Jun 22;8(1):9517. doi: 10.1038/s41598-018-27912-1.

27.

Inherently Radiopaque Narrow-Size-Calibrated Microspheres: Proof of Principle in a Pig Embolization Model.

Sommer CM, Harms A, Do TD, Gockner TL, Kriegsmann M, Schlett CL, Holzer K, Vollherbst D, Warth A, Pereira PL, Eichwald V, Jugold M, Kauczor HU, Flechsig P.

Cardiovasc Intervent Radiol. 2018 Sep;41(9):1404-1411. doi: 10.1007/s00270-018-1986-0. Epub 2018 Jun 1.

PMID:
29858644
28.

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.

Keppens C, Tack V, Hart N', Tembuyser L, Ryska A, Pauwels P, Zwaenepoel K, Schuuring E, Cabillic F, Tornillo L, Warth A, Weichert W, Dequeker E; EQA assessors expert group.

Oncotarget. 2018 Apr 17;9(29):20524-20538. doi: 10.18632/oncotarget.24980. eCollection 2018 Apr 17.

29.

The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC).

Muley T, Rolny V, He Y, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Dienemann H, Meister M, Herth FJ, Dayyani F.

Lung Cancer. 2018 Jun;120:46-53. doi: 10.1016/j.lungcan.2018.03.015. Epub 2018 Mar 17.

30.

Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells.

Gaiser MR, Weis CA, Gaiser T, Jiang H, Buder-Bakhaya K, Herpel E, Warth A, Xiao Y, Miao L, Brownell I.

Oncoimmunology. 2018 Feb 8;7(5):e1426517. doi: 10.1080/2162402X.2018.1426517. eCollection 2018.

31.

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix.

Jesinghaus M, Strehl J, Boxberg M, Brühl F, Wenzel A, Konukiewitz B, Schlitter AM, Steiger K, Warth A, Schnelzer A, Kiechle M, Beckmann MW, Noske A, Hartmann A, Mehlhorn G, Koch MC, Weichert W.

J Pathol Clin Res. 2018 Apr;4(2):93-102. doi: 10.1002/cjp2.95. Epub 2018 Mar 8.

32.

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787. doi: 10.1164/rccm.201708-1707OC.

PMID:
29617574
33.

PD-L1 expression in large cell neuroendocrine carcinoma of the lung.

Eichhorn F, Harms A, Warth A, Muley T, Winter H, Eichhorn ME.

Lung Cancer. 2018 Apr;118:76-82. doi: 10.1016/j.lungcan.2018.02.003. Epub 2018 Feb 6.

PMID:
29572007
34.

[Aerogenic tumor seeding : A new invasive criterion for lung carcinomas].

Warth A, Fink L.

Pathologe. 2018 May;39(3):236-241. doi: 10.1007/s00292-018-0429-7. Review. German.

PMID:
29523927
35.

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Brunnemer E, Wälscher J, Tenenbaum S, Hausmanns J, Schulze K, Seiter M, Heussel CP, Warth A, Herth FJF, Kreuter M.

Respiration. 2018;95(5):301-309. doi: 10.1159/000485933. Epub 2018 Feb 28.

36.

Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.

Kriegsmann M, Harms A, Kazdal D, Fischer S, Stenzinger A, Leichsenring J, Penzel R, Longuespée R, Kriegsmann K, Muley T, Safi S, Warth A.

Pathol Res Pract. 2018 Mar;214(3):408-416. doi: 10.1016/j.prp.2017.12.018. Epub 2018 Jan 2.

PMID:
29487011
37.

Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices.

Bernhardt D, König L, Aufderstrasse S, Krisam J, Hoerner-Rieber J, Adeberg S, Bozorgmehr F, El Shafie R, Lang K, Kappes J, Thomas M, Herth F, Heußel CP, Warth A, Marcrom S, Debus J, Steins M, Rieken S.

Clin Lung Cancer. 2018 Jul;19(4):340-345. doi: 10.1016/j.cllc.2017.12.004. Epub 2017 Dec 15.

PMID:
29373273
38.

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M.

Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24.

39.

Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients.

González-Vallinas M, Rodríguez-Paredes M, Albrecht M, Sticht C, Stichel D, Gutekunst J, Pitea A, Sass S, Sánchez-Rivera FJ, Lorenzo-Bermejo J, Schmitt J, De La Torre C, Warth A, Theis FJ, Müller NS, Gretz N, Muley T, Meister M, Tschaharganeh DF, Schirmacher P, Matthäus F, Breuhahn K.

Mol Cancer Res. 2018 Mar;16(3):390-402. doi: 10.1158/1541-7786.MCR-17-0334. Epub 2018 Jan 12.

40.

Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.

Morath I, Jung C, Lévêque R, Linfeng C, Toillon RA, Warth A, Orian-Rousseau V.

Oncogene. 2018 Mar;37(11):1472-1484. doi: 10.1038/s41388-017-0030-1. Epub 2018 Jan 11.

PMID:
29321661
41.

FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.

Milewski D, Balli D, Ustiyan V, Le T, Dienemann H, Warth A, Breuhahn K, Whitsett JA, Kalinichenko VV, Kalin TV.

PLoS Genet. 2017 Dec 21;13(12):e1007097. doi: 10.1371/journal.pgen.1007097. eCollection 2017 Dec.

42.

Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas.

Kriegsmann M, Harms A, Longuespée R, Muley T, Winter H, Kriegsmann K, Kazdal D, Goeppert B, Pathil A, Warth A.

Histopathology. 2018 May;72(6):997-1006. doi: 10.1111/his.13455. Epub 2018 Feb 20.

PMID:
29243296
43.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

44.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

PMID:
29186353
45.

C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.

Yamauchi Y, Safi S, Muley T, Warth A, Herth FJF, Dienemann H, Hoffmann H, Eichhorn ME.

Lung Cancer. 2017 Dec;114:62-67. doi: 10.1016/j.lungcan.2017.11.002. Epub 2017 Nov 3.

PMID:
29173768
46.

Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages.

Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, Meister M, Muley T, Warth A, Platten M, Hentze MW, Cerwenka A, Muckenthaler MU.

Front Immunol. 2017 Nov 8;8:1479. doi: 10.3389/fimmu.2017.01479. eCollection 2017.

47.

Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.

Safi S, Yamauchi Y, Rathinasamy A, Stamova S, Eichhorn M, Warth A, Rauch G, Dienemann H, Hoffmann H, Beckhove P.

Oncoimmunology. 2017 Sep 8;6(11):e1360458. doi: 10.1080/2162402X.2017.1360458. eCollection 2017.

48.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

49.

[What could the pancreas have to do with shoulder pain?]

Caf P, Kunz J, Flechsig P, Ullrich E, Reimer P, Barreto MM, Kappes J, Herth FJ, Warth A, Kauczor HU, Heußel CP.

Med Klin Intensivmed Notfmed. 2018 Mar;113(2):135-138. doi: 10.1007/s00063-017-0374-x. Epub 2017 Nov 8. German. No abstract available.

PMID:
29119210
50.

Spread through air spaces (STAS): a comprehensive update.

Warth A.

Transl Lung Cancer Res. 2017 Oct;6(5):501-507. doi: 10.21037/tlcr.2017.06.08. Review.

Supplemental Content

Support Center